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Introduction: In this case series and short review of the literature, we underline the impact of nephrectomy
combined with sequential therapy based on cytokines, antiangiogenic factors, and mammalian target of rapamycin
inhibitors along with metastasectomy on overall survival and quality of life in patients with metastatic clear cell
renal carcinoma.
Case presentation: In the first of two cases reported here, a 53-year-old Caucasian man underwent a radical left
nephrectomy for renal cell cancer and relapsed with a bone metastasis in his right humerus. He was treated with
closed nailing and cytokine-based chemotherapy. For 5 years, the disease was stable and he had great
improvement in quality of life. Subsequently, the disease relapsed in his lymph nodes, lung, and thorax soft tissue.
He was then treated with antiangiogenic factors and mammalian target of rapamycin inhibitors. The disease
progressed until September 2009, when he died of allergic shock during a blood transfusion, 9 years after the initial
diagnosis of renal cell cancer.
In the second case, a 54-year-old Caucasian man underwent a radical left nephrectomy for renal cell cancer. A year
later, the disease progressed to his neck lymph nodes, and cytokine-based chemotherapy was initiated. While he
was on cytokines, a solitary pulmonary nodule appeared and he underwent a metastasectomy. Nine months later,
magnetic resonance imaging of his brain revealed a focal right occipitoparietal lesion, which was resected. After
two years of active surveillance, the disease relapsed as a pulmonary metastasis and he was treated with an
antiangiogenic factor. Further progressions presenting as enlarged axillary lymph nodes, chest soft tissue lesions,
and thoracic spine bone metastases were sequentially observed. He then received a first-generation mammalian
target of rapamycin inhibitor, an antiangiogenic factor, and later a second-generation mammalian target of
rapamycin inhibitor and palliative radiotherapy. Ten years after the initial diagnosis of renal cell cancer, his disease is
stable and he is on a third antiangiogenic factor and leads an active life.
Conclusions: One multidisciplinary approach to patients with metastatic renal cell cancer combines nephrectomy,
metastasectomy, and radiotherapy (when feasible) with medical therapy based on cytokines and targeted
treatment employing agents inhibiting angiogenesis, other receptor tyrosine kinases, and mammalian target of
rapamycin. This approach could prolong survival and improve quality of life.
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Figure 1 Closed nailing of the right humerus.
Figure 2 Right humerus nail replacement.
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Renal cell carcinoma (RCC), a relatively common malig-
nancy, accounts for 2% to 3% of all malignant tumors in
adults [1]. In Europe, it has a rising incidence and repre-
sents the third most prevalent urologic malignancy: RCC
is diagnosed in 40,000 patients each year. Patients with
untreated metastatic RCC (mRCC) have a 5-year sur-
vival rate of only 0% to 18%, whereas patients with RCC
of any stage have a 5-year survival rate of 62% [2,3], indi-
cating an aggressive malignancy. At the time of diagno-
sis, one third of patients present with locally advanced
or metastatic disease and one third of patients undergo-
ing cytoreductive nephrectomy will experience relapse
and develop metastasis [4]. In these settings, first-line
medical treatment is recommended. The current man-
agement of mRCC is challenging given the various
therapeutic options available after the development of
several new targeted drugs. Until relatively recently,
cytokine treatment with interferon-alpha (IFN-α) and
interleukin-2 was the gold standard of treatment. Only
after the approval of antiangiogenic agents that directly
inhibit vascular endothelial growth factor (VEGF) (beva-
cizumab), others that target VEGF receptors and tyro-
sine kinase receptors (sorafenib, sunitinib, pazopanib,
and axitinib), and factors that inhibit the mammalian
target of rapamycin (mTOR) (temsirolimus and everoli-
mus) did patients with mRCC experience higher re-
sponse rates and prolonged survival [5]. With the
development of these agents, the progression-free sur-
vival (PFS) has practically doubled, and up to 30% of
patients achieve partial remission [2]. According to
emerging evidence, administering these drugs sequen-




In September 2000, a 53-year-old Caucasian man who
was a heavy smoker underwent a radical left nephrec-
tomy for a grade 1, stage I, renal clear cell carcinoma
revealed on a routine abdominal ultrasound exam. In
July 2001, he presented with a dull pain in his right hu-
merus which rapidly worsened. The pain caused the pa-
tient, a professional musician, such discomfort that he
was forced to stop playing his instrument (the bouzouki,
a stringed instrument from Greece), and strong opioids
were required for pain control. The results of a com-
puted tomography (CT) scan of his right humerus and a
technetium bone scan showed a solitary bone metastasis.
He was treated with closed nailing of his right humerus,
but total resection of the metastasis was not achieved
(Figure 1). He was put on cytokine-based chemotherapy
from May 2002 to February 2003. The chemotherapy
consisted of IFN-α2α 6MU administered subcutaneouslythree times per week, recombinant human interleukin-2
at a dose of 9×106IU subcutaneously for 4 weeks fol-
lowed by 1 week of rest, and vinorelbine 30mg/m2 and
zolendronic acid 4mg every 21 days. Then he underwent
a right humerus nail replacement with 10-fraction radio-
therapy in order to render his extremity pain-free and
capable of weight-bearing (Figure 2). He was offered
physiotherapy but declined. He received IFN-α treat-
ment for a further 4 months and, notably, resumed
playing the bouzouki, which requires significant upper-
extremity dexterity, attesting to a dramatic improvement
of his symptoms. His disease was stable and he led an
active life from September 2003 to June 2008, when a
chest CT scan revealed several enlarged subcarinal, left
hilar, and axillary lymph nodes. He was treated with
sunitinib at 50mg/day for 4 weeks with a 2-week wash-
out phase along with vinorelbine 30mg/m2, bevacizumab
200mg, and zolendronic acid every 21 days. A partial re-
sponse was observed until February 2009, when a chest
CT scan revealed several pulmonary nodes consistent
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at 25mg weekly until June 2009, when he experienced
further deterioration with pleural effusions and a soft tis-
sue metastasis of his thorax. He received sorafenib at
800mg/day along with bevacizumab at 200mg weekly
and developed a grade III anemia that impacted nega-
tively on his performance status and that was treated
with erythropoiesis-stimulating agents and blood trans-
fusions. The disease progressed until September 2009,
when he died of allergic shock during a blood transfu-
sion, 9 years after the initial diagnosis of RCC.
Case 2
A 54-year-old Caucasian man, a civil engineer, presented
with acute urinary retention in July 2002. An abdominal
CT scan showed a mass in his left kidney, and he under-
went an uneventful radical left nephrectomy for a pT2,
grade IV renal clear cell carcinoma. On August 2003, a
physical examination revealed an enlarged supraclavicu-
lar lymph node, which was histologically proven to be
RCC. He was put on cytokine-based chemotherapy –
IFN-α 6MU subcutaneously 3 days per week, and doce-
taxel 60mg and vinorelbine 50mg every 21 days – until
November 2004, when a nodule at the upper lobe of his
right lung was found on a chest CT scan. The biopsy of
the solitary pulmonary nodule confirmed an RCC metas-
tasis, and he underwent a metastasectomy. On Septem-
ber 2005, a magnetic resonance tomography scan of his
brain revealed a focal lesion, 3cm in diameter, at the
right occipitoparietal region. Two months later, the soli-
tary brain metastasis was resected and was histologically
proven to be RCC. In March 2007, a new solitary pul-
monary nodule in his lower right lobe was found, and
sunitinib at 50mg/day for 4 weeks with a 2-week wash-
out phase was administered. The disease was stable until
February 2008, when a chest CT scan revealed bilateral
enlargement of axillary lymph nodes, a lesion with soft
tissue density in the anterior aspect of the right pulmon-
ary artery, and another one in the hilus of the left lung.
Owing to his progressive disease, temsirolimus at 25mg
weekly was initiated. Three months after temsirolimus
initiation, intravenous zolendronic acid every 21 days
was added because of the appearance of new bone me-
tastases involving thoracic vertebrae. A partial response
was observed until October 2008, when the soft tissue
density lesions progressed and treatment with sorafenib
400mg/day was initiated. The disease was stable until
June 2010, when a new pulmonary nodule appeared and
the bone metastases became painful. Then the patient
was treated with a second-generation mTOR inhibitor,
everolimus 10mg by mouth every day, and 6-fraction
palliative radiotherapy was applied to the painful spine
bone metastases at a total dose of 24Gy. His disease was
rendered stable for a year, when a new pulmonarymetastasis appeared. The patient has since been receiv-
ing pazopanib at 800mg/day, resulting in stable disease
to the present day. Ten years after the diagnosis of RCC,
he leads an active life and only moderate bone pain pre-
vents him from doing strenuous activity.
Discussion
Clear cell RCC accounts for 70% to 75% of all histologic
subtypes of RCC [7]. It may progress insidiously over a
span of years, but once metastasis becomes evident, the
5-year survival rate declines sharply from more than 50%
to 6% [8]. Nephrectomy or nephron-sparing surgery has
been proven to be of benefit and is usually performed
even in the setting of mRCC, except for poor-prognosis
patients, according to criteria of the Memorial Sloan-
Kettering Cancer Center [9]. Both cases presented here
underwent a nephrectomy with curative intention since
their disease was not metastatic at diagnosis, and both
were meticulously followed up with given that there was
no indication for any adjuvant treatment. Once metasta-
ses are present, lungs are commonly affected by a single
metastasis (30.4%) or multiple metastases (75.6%),
whereas bones are affected in 14% of patients with
mRCC. Solitary bone metastasis, mostly a lytic lesion,
may present in up to 26% of mRCC cases and confers a
5-year survival rate of 11% [10]. The most common loca-
tions of bone metastases from RCC are the spine, pelvis,
femur, scapula, and humerus. Since they are highly de-
structive vascular lesions, they pose significant surgical
challenges due to the risk of life-threatening hemorrhage
and are resistant to other treatments. However, patients
with a solitary bone metastasis have the most favorable
overall survival [11]. Althausen et al. [12] report that
those patients with solitary osseous metastasis and the
longest interval between the diagnosis of RCC and the
diagnosis of the metastasis have a relatively favorable
prognosis and these carcinomas should be treated as rad-
ically as possible, whereas Kavolius et al. [13] report that
resection of solitary metachronous RCC metastases from
RCC is associated with a 5-year survival rate of 35% to
50%. Case 1 had a metachronous right humerus solitary
metastasis, which appeared 1 year after the diagnosis of
RCC. Given the relatively favorable clinical setting and
the fact that the patient experienced a very significant de-
terioration in quality of life and even had to stop work-
ing, he underwent an orthopedic surgical procedure
followed by radiotherapy. Indeed, implant stability and
local control of disease were achieved and his extremity
was rendered pain-free and capable of weight-bearing.
Subsequently, he received cytokine-based chemotherapy
– which consisted of IFN-α 6MU subcutaneously,
interleukin-2 at a dose of 9×106IU, vinorelbine 30mg,
and zolendronic acid 4mg every 21 days – because total
resection of the metastasis was not feasible. The outcome
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job, which required rapid, fine, and coordinated upper-
extremity movements.
Lung metastases are also a relevant therapeutic chal-
lenge. The 5-year survival rate after complete resection
of pulmonary metastasis from RCC is up to 60% [3].
Volkmer et al. [14] report that the survival rate is signifi-
cantly higher after resection of pulmonary metastases
than after resection of extrapulmonary metastases. In
case 2 presented here, a solitary metastatic nodule at the
upper lobe of his right lung appeared 20 months after
the initial diagnosis of RCC. The presence of a solitary
metastasis, a long interval between the diagnosis of RCC
and the diagnosis of metastasis, and a good performance
status indicated a favorable clinical setting for resection,
and the patient underwent a metastasectomy.
Brain metastases usually develop as a late manifest-
ation of RCC and pose an increasing challenge to oncol-
ogists. Pomer et al. [15] defined a subgroup of patients
who had a significant benefit from aggressive treatment
of brain metastases. Patients with a metachronous ap-
pearance of brain metastases more than 1 year after
nephrectomy, good performance status, age of less than
50 years, minimal or no neurological deficit, and min-
imal extracranial metastases showed a trend toward
improved survival with metastasectomy. Also, the
authors showed that surgical treatment of recurrent
brain tumors yielded an additional median survival ad-
vantage of 8 months as compared with untreated
patients [15]. Case 2 had a focal lesion at the right occi-
pitoparietal region a year after metastasectomy for the
lung lesion was performed. He had favorable clinical
attributes as defined in the study by Pomer et al. There-
fore, the solitary brain metastasis was resected.
We consider that the long survival of the two cases
could be attributable to the positive patient profile that
favored metastasectomies and to the sequential medical
therapy, which consisted of cytokines, tyrosine kinase re-
ceptor inhibitors, and inhibitors of the mTOR.
Cytokines were considered the cornerstone of the
treatment of RCC, and IFN-α and interleukin-2 yielded
durable, albeit rare, complete remissions in certain sub-
groups [16]. Systemic therapies employed in patients
with mRCC included classic cytotoxic agents such as
vinorelbine and gemcitabine along with cytokines with
some promising results [17,18]. After the favorable set-
ting of the disease was taken into consideration, both
cases of the study were offered first-line cytokine-based
therapy along with standard chemotherapy agents (the
clinical practice at the time) in order to achieve a pro-
longed overall survival.
According to clinical evidence, sequential targeted
therapy is recommended in patients with mRCC and
confers improved responses and prolonged survival.Bellmunt et al. [5] report the goals of the sequential
therapy: achieving a treatment continuum (with the
intention of maintaining patients on treatment without
progression for as long as possible), attaining full dose
intensity of targeted agents, ensuring that patients are
exposed to optimal drug levels, minimizing adverse
effects, and maximizing clinical benefit. Additionally,
targeting different pathways through sequential therapy
may offer an advantage in terms of overcoming resist-
ance to individual agents [19].
Another pathway involved in RCC growth, prolifera-
tion, angiogenesis, and potential for metastasis is the
mTOR. Temsirolimus inhibits mTOR in the PI3K-Akt
pathway and is a recommended first-line regimen for
the poor-risk patient group [25]. In anti-VEGF refrac-
tory mRCC, everolimus, a novel orally administered
mTOR inhibitor, is indicated [26]. Many targeted drugs
have been developed over the last decade, and others,
including etaracizumab, vorinostat, XL880, and inflixi-
mab, are currently under study.
In terms of toxicity, patients treated with tyrosine
kinase inhibitors may experience several adverse effects
such as fatigue, hypertension, proteinuria, cardiac tox-
icity, hypothyroidism, hematological effects, hand-foot
syndrome, mucositis, and gastrointestinal toxicities. The
VEGF antibody-cytokine combination presents a differ-
ent pattern of toxicity, including gastrointestinal per-
foration, bleeding, thromboembolic events, proteinuria,
anorexia, and fever. The adverse event profile of mTOR
includes hyperglycemia, hyperlipidemia, asthenia, hem-
atological toxicity, pneumonitis, infections, and muco-
sitis [27].
Case 1 experienced only mild hypertension attributed
to sunitinib that was successfully treated with an angio-
tensin II receptor blocker. However, he experienced
grade III anemia when therapy was switched to temsiro-
limus and was treated with erythropoiesis-stimulating
agents and blood transfusions. The cause of death of this
patient, an uncontrollable allergic reaction to a blood
transfusion, could be considered an indirect effect of
temsirolimus-induced anemia.
Case 2 developed clinical hypothyroidism 6 months
after sunitinib initiation and was offered levothyroxine.
Temsirolimus was well tolerated, and sorafenib caused
only mild asthenia, grade I myelosupression, and hyper-
lipidemia. Treatment with pazopanib caused anorexia
and grade II diarrhea. Notably, in both cases, no treat-
ment delay or dose reduction was needed.
The combination of these agents and the time and the
sequence of administration seem to be the key factors
for a successful treatment. In the cases reported here,
we intended to target different points of the same cellu-
lar pathway or different pathways in order to offer the
patients the maximum therapeutic advantage, given the
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ment. We tend to attribute the long-term survival
achieved to the sequential medical treatment. Recent
studies suggest that, even after a VEGFR inhibitor fail-
ure, a switch to another VEGFR inhibitor could still be
effective given that the targets are overlapping but not
identical [28]. Additionally, a failure of a previous anti-
VEGF therapy might not preclude failure of a VEGFR in-
hibition given the activity seen using sunitinib in
patients refractory to bevacizumab. This theory could be
consistent with our experience.
Resistance to anti-VEGF therapy may arise through
the development of alternative angiogenic pathways. A
proposed strategy to overcome resistance is to combine
antiangiogenic agents with different mechanisms of ac-
tion [19]. Thus, case 1 was treated with a sorafenib and
bevacizumab doublet to overcome the eventual resist-
ance caused by previous treatment with sunitinib.
Also, the interdisciplinary task force of the German
Cancer Society (DKG) suggested that targeted therapies
should strive for a sufficient treatment duration in each
line of therapy in order to achieve the best therapeutic
outcome [29], whereas Staehler et al. [2] suggested that
systemic antiangiogenic therapy should be continued
even if there is no evidence of disease.
Kirchner et al. [27] proposed a patient-based treatment
strategy based mainly on the tumor burden and the de-
velopment of the disease to try to find a balance between
tumor burden and quality of life and thus to obtain the
best outcome for the patient. In this study, patients with
a high tumor burden were treated with sunitinib,
whereas sorafenib was preferred when tumor control was
the main focus, conferring better quality of life.
According to the pace of the disease, the cases in our
study were under careful surveillance and were offered
best supportive care after being treated with metastasec-
tomies, since the residual tumor burden was not life-
threatening. Both cases were treated with sunitinib at
their further relapse targeting a high remission rate.
From our experience, we could possibly attribute the
long-term survival of the patients in part to the multi-
modal treatment and in part to the use of multiple thera-
peutic agents. The clinical strategy to treat RCC patients
who have a solitary metastasis and a good performance
status with metastasectomy and continuous sequential
therapy with cytokines and new targeted agents could be
given consideration according to the patient’s individual
characteristics and current guidelines.
Beyond overall survival and PFS, it is fundamental to
distinguish which therapies offer a major benefit in
terms of quality of life. Only a few studies have reported
an advantage in quality of life when VEGFR inhibitors
are administered. Cella et al. [30] and Escudier et al.
[31] reported improved quality of life in patients treatedwith sunitinib and sorafenib, respectively. In case 1, the
dramatic improvement in quality of life could be attribu-
ted to the multimodal character of treatment, which
consisted of an orthopedic surgical procedure followed
by radiotherapy and systemic cytokine-based chemother-
apy. mRCC should be broadly considered a systematic
disease demanding multimodal treatment that should
ideally be coordinated by a multidisciplinary working
group in experienced centers.
Conclusions
Patients with untreated mRCC have a 5-year survival
rate of less than 20%. Several treatment modalities that
may prolong survival and improve quality of life are at
our disposal. Here, we present two patients whose RCC
was treated with nephrectomy, metastasectomies, and
sequential systemic therapy and who experienced a very
satisfactory quality of life and long-term survival. Metas-
tasectomy, when feasible, could be considered a clinical
option, especially in patients with favorable characteris-
tics. Sequential medical therapy based on cytokines and
on an array of targeted treatment agents such as tyrosine
kinase receptor inhibitors, humanized monoclonal anti-
bodies against vascular endothelial growth factor, and
mTOR inhibitors may be established as a routine prac-
tice in the treatment of mRCC in selected patients. The
effects of multimodal treatment and sequential use of
established or experimental targeted agents should be
studied further. Ideally, randomized clinical trials and
open-label trials that reflect real-life clinical practice
with endpoints that include quality of life and preven-
tion of disability should be undertaken in order to
optimize our current treatment strategy. It is conceivable
that current guidelines could be amended, leading to an
increase in the number of RCC patients who achieve
long-term survival and an acceptable quality of life.
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